Table 2 Some examples of various formats of scfvs in the market or clinical trails
From: A comprehensive comparison between camelid nanobodies and single chain variable fragments
Format | Antibody fragment | Target | Disease | Clinical trials | Phase | Status | Last update / approval date | Sponser |
|---|---|---|---|---|---|---|---|---|
Unconjugated neutralizing agent | Brolucizumab | Vascular endothelial growth factor A (VEGFA) | neovascular age-related macular degeneration (AMD) | NCT03386474 | 3 | FDA approved | Oct 2019 | Novartis |
| Â | Emicizumab | Factor VIII | Hemophilia A | NCT02795767 | 3 | FDA approved | Oct 2018 | Hoffmann-La Roche |
| Â | Dinutuximab | GD2 | neuroblastoma | NCT03098030 | 2&3 | FDA approved | Apr 2015 | United Therapeutics |
Conjugated to immune cell engaging antibody fragments | Blinatumomab | CD19 | Lymphoblastic Leukemia | NCT02393859 | 3 | FDA approved | Mar 2018 | Amgen |
| Â | Duvortuxizumab | CD19, CD3E | B-cell Malignancies | NCT02454270 | 1 | Terminated | Dec 2018 | Janssen Research & Development |
Targeting moiety of nanocarriers | SGT 53 | transferrin receptor (TfR) | Solid Tumors | NCT02340156 | 2 | terminated | Mar 2021 | SynerGene Therapeutics |
| Â | SGT-94 | transferrin receptor (TfR) | Solid Tumors | NCT01517464 | 1 | completed | Apr 2017 | SynerGene Therapeutics |
| Â | MM-302 | HER2 | Breast Cancer | NCT02213744 | 2&3 | terminated | Jan 2017 | Merrimack Pharmaceuticals |
Antigen binding domain in synthetic Receptors | Ciloleucel Yescarta | CD19 | Diffuse large B-cell lymphoma (DLBCL) | NCT03391466 | 3 | FDA approved | Oct 2017 | Gilead |
| Â | Tisagenlecleucel Kymirah | CD19 | Non-Hodgkin Lymphoma | NCT03570892 | 3 | FDA approved | Aug 2017 | Novartis |
| Â | Brexucabtagene | CD19 | Relapsed/Refractory Mantle Cell Lymphoma | NCT02601313 | 2 | FDA approved | Jul 2020 | Gilead |
| Â | Lisocabtagene Maraleucel | CD19 | Non-Hodgkin, B-Cell, Large B-Cell lymphoma | NCT03483103 | 2 | FDA approved | Feb 2021 | Celgene |
| Â | idecabtagene vicleucel | CD19 | Multiple Myeloma | NCT03361748 | 2 | FDA approved | Aug 2021 | Celgene |